Laidlaw Venture Partners portfolio company Amesite (AMST) announces pricing of Initial Public Offering of $15,000,000.
Laidlaw acted as the Sole Book-Runner, and previously completed the companies Series A and B rounds over the last two years.
Laidlaw Venture Partners Continues Strategic Growth with Addition of Mr. Anthony Zook to its Investment and Operations Committee
Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the addition of Mr. Anthony (‘Tony’) Zook to its newly formed Investment and Operations Committee. As a global industry leader, Zook brings years of strategic experience to Laidlaw Venture Partners and is expected to be instrumental in the further development and evolution of the LVP portfolio of companies.
Laidlaw served as Financial Advisor on the $173,000,000 Follow-On Offering for Arcturus Therapeutics (ARCT)
Laidlaw Capital Markets is pleased to have served as Financial Advisor to Arcturus Therapeutics on its $173,000,000 financing alongside Citigroup, Guggenheim Securities, and Barclays. Laidlaw has helped Arcturus in its efforts in 2020 raise approximately $250,000,000.
Laidlaw Venture Partners’ portfolio company Amesite CEO, Dr. Ann Marie Sastry, back on CNBC’s Squawk Box.
Ann Marie Sastry, founder and CEO of Amesite, joins “Squawk Box” to discuss how the Covid-19 pandemic is changing remote learnings for students and workers looking to continue their education.”
Laidlaw Venture Partners Continues Strategic Growth with Addition of Jeff Conroy and George Serafin to its Board of Advisors
Laidlaw Venture Partners, the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the addition of Jeff Conroy and George Serafin to its Board of Advisors. As industry leaders in Business Development and Regulatory/Compliance, both Conroy and Serafin bring years of strategic experience to Laidlaw Venture Partners and will be instrumental in the development and evolution of our innovative companies.
Laidlaw served as Co-Manager on the $50,000,000 Follow-On Offering for Soleno Therapeutics (SLNO) with Guggenheim Partners
Laidlaw is pleased to have Co-Managed a $50,000,000 deal for Soleno Therapeutics (SLNO) with Guggenheim Partners.
Laidlaw Venture Partners Adds Industry Leading CEOs Jeffrey O’Donnell and Dr. Ann Marie Sastry to its Board of Advisors
Laidlaw Venture Partners, the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the addition of Jeff Conroy and George Serafin to its Board of Advisors. As industry leaders in Business Development and Regulatory/Compliance, both Conroy and Serafin bring years of strategic experience to Laidlaw Venture Partners and will be instrumental in the development and evolution of our innovative companies.
Laidlaw served as Sole Book-Runner on the $5mm Follow-On Offering for Hoth Therapeutics (HOTH)
Laidlaw Capital Markets is pleased to announce yesterday’s pricing of a $5,000,000 Follow-On Offering for Hoth Therapeutics (HOTH). Laidlaw proudly served as the Sole Book Runner on the transaction.
Laidlaw served as Introducing Broker on the $10.8mm financing for Biosig Technologies (BSGM), through its subsidiary ViralClear.
Laidlaw Venture Partners client Biosig Technologies (BSGM) through its newly formed subsidiary ViralClear, closes $10,800,000 financing. Laidlaw is proud to have acted as am Introducing Broker on this financing.
Laidlaw served as Co-Lead Manager on the $22mm financing and uplisting for Delcath Systems (DCTH)
Laidlaw Capital Markets is pleased to have acted as Co-Lead Manager on Delcath Systems’ (DCTH) $22,000,000 financing and uplisting to NASDAQ. Laidlaw proudly served as the Sole Book Runner on the transaction.
COVID-19 Letter